Terminated PHASE3 INTERVENTIONAL 2-arm NCT00912444

Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer (NATT)

A Multi-Center, Randomized Study of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Neoadjuvant Treatment of Triple-Negative or Her2 Positive Breast Cancer

Sponsor: Shanghai Jiao Tong University School of Medicine

Conditions Breast Cancer

Interventions Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide Docetaxel, cyclophosphamide

Updated 10 times since 2017 Last updated: Nov 19, 2016 Started: Jul 31, 2009 Primary completion: May 31, 2012 Completion: Oct 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

TAC treatment was associated with better survial outcome compared with TC treatment, we terminated recruiting and waiting for longer follow up period.

Other terminated trials from Shanghai Jiao Tong University School of Medicine

See all terminations from Shanghai Jiao Tong University School of Medicine

Other Breast Cancer trials with similar outcome

Browse all Breast Cancer trials

This PHASE3 trial investigates Breast Cancer and is currently terminated or withdrawn. Shanghai Jiao Tong University School of Medicine leads this study, which shows 10 recorded versions since 2009 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE3

▶ Show 5 earlier versions

Nov 2020 — Jan 2021 [monthly]

Terminated PHASE3
Jun 2018 — Nov 2020 [monthly]

Terminated PHASE3
May 2018 — Jun 2018 [monthly]

Terminated PHASE3
Aug 2017 — May 2018 [monthly]

Terminated PHASE3
Jan 2017 — Aug 2017 [monthly]

Terminated PHASE3

First recorded

Jul 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Jiao Tong University School of Medicine

Data source: Shanghai Jiao Tong University School of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Changsha, China , Chengdu, China , Foshan, China , Guangzhou, China , Hangzhou, China , Jiangyin, China , Kunming, China , Linyi, China , Nanchang, China , Nanjing, China and 9 more locations